Market research
KLRS Kalaris Therapeutics, Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 80M
- P/E ratio
- Not available
- Analyst target
- 18.7143
- Dividend yield
- Not available
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4829291065
- Market cap
- 80M
- P/E ratio
- Not available
- Analyst target
- 18.7143
- Dividend yield
- Not available
- Beta
- Not available
About
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the KLRS discussion.
No comments yet
Start a focused discussion about KLRS.